A
Adenocyte
Health · Israel · Founded 2020
LINFU® enhances epithelial cell exfoliation with low-intensity ultrasound, improving cytological specimens for cancer screening MoreLess
Adenocyte is focused on improving the early detection of dysplasia and cancer through enhanced cytological specimens. The company's core technology utilizes a specially designed, low-intensity, non-focused ultrasound beam.
This FDA-cleared device is applied extracorporeally in a brief procedure to increase the natural rate of epithelial cell exfoliation into a surrounding body fluid. The result is a dramatically improved sample for laboratory analysis.
The primary application is to aid in the early detection and prevention of cancers, with a specific mention of pancreatic cancer. By providing a better sample, the company aims to increase the effectiveness of cancer screening procedures.
The company's Director of Technical Operations, Aaron Rutenberg, brings over a decade of experience in coordinating R&D projects for biomedical firms, with a background in diagnostics and laboratory management.
Keywords: ultrasound, cytopathology, cancer screening, dysplasia, epithelial cell, exfoliation, diagnostics, medical device, pancreatic cancer, FDA cleared
Company overview
Adenocyte company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2020
- Headquarters
- Israel
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 24.0
Valuation & funding
Adenocyte funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | May 2026 | $10M | $40M | IGan Partners | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 3 |
Growth signals
Adenocyte website traffic
Latest recorded traffic for Adenocyte is 910 monthly website visits, up 139.5% over the last three months.
Comparisons
Adenocyte compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Adenocyte's talent
Source: Dealroom Talent Intelligence.
Investors
1 investor on Adenocyte's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Adenocyte has talent and traffic
team presence
In the news
Latest news about Adenocyte
Recent press, funding announcements, and product moves mentioning Adenocyte — open to read from the original sources.
Market sentiment
What the market is saying about Adenocyte
An AI-synthesized read of the highest-engagement posts about Adenocyte on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adenocyte’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.